Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

News SummaryMost relevantAll newsSector newsTweets 

Biocon, Bristol-Myers Squibb Sign Pact for Experimental Oral Insulin Drug

share with twitter share with LinkedIn share with facebook
share via e-mail
11/16/2012 | 05:26am CEST
   By Rumman Ahmed 

BANGALORE, India--Biocon Ltd. (532523.BY) Friday said it has entered into an agreement with Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) on a licensing deal for its experimental biopharmaceutical drug IN-105, which is an orally administered insulin.

Under the terms of the agreement, the New York-headquartered company will have the right to exercise an option to obtain a global license for IN-105 on the successful completion of mid-stage trials for the experimental drug by Biocon, the Indian company said in a statement.

Biocon, which develops biological treatments that use proteins manufactured in living cells, is India's largest biotechnology company by revenue.

It has been seeking alliances with other drug makers for further development of the experimental drug under a licensing agreement.

If Bristol-Myers Squibb decides to obtain the license for IN-105, the U.S. company will assume full responsibility for the development program, including all development and commercialization activities outside India, the statement said.

In return, Biocon will receive a license fee, potential payments when IN-105 achieves certain regulatory and commercial milestones, as well as royalties on commercial sales of IN-105 outside India, the statement added.

Biocon will retain exclusive rights to IN-105 in India.

Indian drug makers often seek to develop drugs in partnership with foreign companies because they can help finance costly and lengthy research. At the same time, global companies are keen to cooperate with Indian companies because of lower costs, the availability of skilled scientists in the South Asian country, as well as the prospect of adding new products to their portfolios.

Write to Rumman Ahmed at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
06/22 BRISTOL MYERS SQUIBB : Trademark Application for "ELZITUDE" Filed by Bristol-Mye..
06/22 BRISTOL MYERS SQUIBB : An Application for the Trademark "EMKELOS" Has Been Filed..
06/22 BRISTOL MYERS SQUIBB : to Announce Results for Second Quarter 2017 on July 27
06/22 BRISTOL MYERS SQUIBB : Extended Follow-Up Data Evaluating Opdivo nivolumab Shows..
06/22 BRISTOL MYERS SQUIBB : Supreme Court ruling could make it harder to file class-a..
06/21 BRISTOL MYERS SQUIBB : Announces the Expiration of its Cash Tender Offer
06/20 BRISTOL MYERS SQUIBB : Announces the Pricing Terms of its Cash Tender Offer For ..
06/20 BRISTOL MYERS SQUIBB : In WLF Victory, Supreme Court's Bristol-Myers Decision Li..
06/20DJBRISTOL MYERS SQUIBB : Drug Suits Suffer Setback -- WSJ
06/20 U.S. Supreme Court again limits where companies can be sued
More news
Sector news : Pharmaceuticals - NEC
06/22 MYLAN : shareholders vote against executive pay, re-elect board
06/22 Health stocks help European equities cut losses
06/22DJR. JOHNSON : Missouri Sues Drug Firms Over Opioid Marketing -- WSJ
06/21DJJOHNSON & JOHNSON : J&J Seeking Dismissal of Talc Lawsuits in Missouri
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
06/22 BIOTECH FORUM DAILY DIGEST : Biotech Breaks Out! Spotlight On Aclaris Therapeuti..
06/22 Drug stocks rally on GOP draft of healthcare bill
06/22 Only Bristol Bucks Big Pharma's Drive For External Reliance
06/21 Biotechs blaze as Trump draft order on drug prices would ease regulations
06/21 TAKEOVER RUMORS DE JOUR : Pfizer taking out Bristol-Myers, ACADIA Pharma
Financials ($)
Sales 2017 20 264 M
EBIT 2017 5 470 M
Net income 2017 4 636 M
Debt 2017 74,3 M
Yield 2017 2,76%
P/E ratio 2017 20,43
P/E ratio 2018 18,69
EV / Sales 2017 4,66x
EV / Sales 2018 4,49x
Capitalization 94 447 M
More Financials
Duration : Period :
Bristol-Myers Squibb Compa Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQU...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 57,1 $
Spread / Average Target -0,34%
Consensus details
EPS Revisions
More Estimates Revisions
Giovanni Caforio Chairman & Chief Executive Officer
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Laurie H. Glimcher Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON17.10%361 566
ROCHE HOLDING LTD.8.81%224 305
NOVARTIS7.69%214 091
PFIZER4.86%199 854
MERCK AND COMPANY12.15%176 500
More Results